MicroStrategy shares briefly top $500, market cap exceeds $110bn in record time

U.S. Stocks Move: Analog Devices Rises Nearly 4% Pre-market as Q1 Earnings Exceed Expectations

Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).

Rosenblatt Securities has upgraded its investment rating for Kunteng Electronics from "Neutral" to "Buy," and has significantly raised its target price from $335 to $360.

Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA).